Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70599 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Peter Erik Lotko Pontoppidan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Clinic of Pediatric Oncology and Hematology Rigshospitalet, University of Copenhagen, Denmark. Hauptthemen laut MEDLINE: Vincristine, Peripheral Nervous System Diseases, Neurofilament Proteins, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danish Childhood Cancer Foundation, Danish Cancer Society, Børnecancerfonden.
Abstract (Originalsprache)
Aims
Vincristine‐induced peripheral neuropathy (VIPN) is a common side effect in children and adolescents treated with vincristine. Assessing VIPN, especially in young children, is challenging due to a lack of sensitive tools. This limits our understanding of the nature and risk factors of VIPN. This study aimed to investigate neurofilament light chain (NfL) as a biomarker of nerve damage in vitro and in vivo .
Methods
Induced pluripotent stem cells (iPSC) were differentiated into sensory neurons (SN) and exposed to incremental concentrations of vincristine. Cells were fixed and immunolabelled to showcase structural damage and media were collected for assessment of NfL. Furthermore, we performed a prospective, self‐controlled clinical trial in 21 children with acute lymphoblastic leukaemia (ALL) during their 36‐day weekly vincristine induction and assessed VIPN symptoms using Common Terminology Criteria for Adverse Events (CTCAE). Blood was drawn before or shortly after initiating treatment and every week following initiation of treatment to assess NfL in serum (sNfL).
Results
In vitro studies using iPSC‐SN showed that vincristine exposure caused substantial structural damage and a dose‐dependent increase in NfL release to cell medium. In this pilot study, median sNfL increased from 8.9 pg/mL pre‐treatment to 158.5 pg/mL by day 36, coinciding with worsening sensory and motor symptoms. However, in this pilot study, no statistically significant correlation between sNfL levels and CTCAE was found.
Conclusion
Vincristine causes concentration‐dependent NfL release in vitro , and sNfL levels increase during vincristine treatment. Further studies are needed to investigate sNfL's potential as a biomarker of VIPN in children with ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Clinic of Pediatric Oncology and Hematology Rigshospitalet, University of Copenhagen, Denmark.
- Pediatric Oncology Research Laboratory, Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Denmark.
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark, University of Southern Denmark, Odense, Denmark.
- Department of Biochemistry and Immunology, Lillebaelt University Hospital Vejle, Odense, Denmark.
- Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Peter Erik Lotko Pontoppidan, Tore Bjerregaard Stage
Förderung
- Danish Childhood Cancer Foundation
- Danish Cancer Society
- Børnecancerfonden
- Kræftens Bekæmpelse
Zitieren
APA
Pontoppidan, P. E. L., Vase, C. B., Mortensen, C., Andres-Jensen, L., Olsen, D. A., Madsen, J. S., Schmiegelow, K., Mathiasen, R., & Stage, T. B. (2026). Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70599
Vancouver
Pontoppidan PEL, Vase CB, Mortensen C, Andres-Jensen L, Olsen DA, Madsen JS, et al. Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70599
BibTeX
@article{Pontoppidan2026,
author = {Pontoppidan, Peter Erik Lotko and Vase, Christian Bach and Mortensen, Christina and Andres-Jensen, Liv and Olsen, Dorte Aalund and Madsen, Jonna Skov and Schmiegelow, Kjeld and Mathiasen, Rene and Stage, Tore Bjerregaard},
title = {Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70599}
}
EUVIMED